Literature DB >> 11110703

Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia.

L Schandené1, F Roufosse, A de Lavareille, P Stordeur, A Efira, B Kennès, E Cogan, M Goldman.   

Abstract

A recent study identified a clonal expansion of CD3(-)CD4(+)cells secreting Th2-type cytokines in 4 patients with chronic hypereosinophilia. Because interferon alpha (IFN-alpha) is used in the therapy of the idiopathic hypereosinophilic syndrome, the effects of this cytokine on the survival of clonal Th2 cells isolated from the blood of 2 patients were determined. First, these cells displayed a high rate of spontaneous apoptosis on culture in cytokine-free medium and were also sensitive to Fas-mediated apoptosis induced by soluble Fas ligand. Addition of IFN-alpha or interleukin-2 (IL-2) to culture medium resulted in significant protection against spontaneous but not Fas-induced apoptosis. Although spontaneous apoptosis of the clonal Th2 cells was clearly associated with down-regulation of both bcl-2 and bcl-x(L) levels, IFN-alpha had no significant effect on the expression of these antiapoptotic proteins, whereas addition of IL-2 resulted in higher levels of bcl-2. On the other hand, IFN-alpha decreased the numbers of cells with disrupted mitochondrial transmembrane potential both during spontaneous apoptosis and after exposure to protoporphyrin IX. Thus, IFN-alpha might promote the survival of clonal Th2 cells, an effect that could be relevant to the therapeutic approach for patients with chronic hypereosinophilia caused by clonal expansion of Th2-type cells. (Blood. 2000;96:4285-4292)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11110703

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Advances in diagnosis and treatment of eosinophilia.

Authors:  Javed Sheikh; Peter F Weller
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

Review 2.  Therapeutic approaches to patients with hypereosinophilic syndromes.

Authors:  Hans-Uwe Simon; Amy Klion
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

Review 3.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2015-05-11       Impact factor: 22.113

Review 4.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2009-08-19       Impact factor: 22.113

Review 5.  Eosinophilic disorders in children.

Authors:  Amy Wagelie-Steffen; Seema S Aceves
Journal:  Curr Allergy Asthma Rep       Date:  2006-11       Impact factor: 4.919

6.  Interferon-alpha administration enhances CD8+ T cell activation in HIV infection.

Authors:  Maura Manion; Benigno Rodriguez; Kathleen Medvik; Gareth Hardy; Clifford V Harding; Robert T Schooley; Richard Pollard; David Asmuth; Robert Murphy; Edward Barker; Kirsten E Brady; Alan Landay; Nick Funderburg; Scott F Sieg; Michael M Lederman
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

Review 7.  Hypereosinophilic syndromes.

Authors:  Florence E Roufosse; Michel Goldman; Elie Cogan
Journal:  Orphanet J Rare Dis       Date:  2007-09-11       Impact factor: 4.123

8.  Successful treatment of steroid resistant hypereosinophilic syndrome with low-dose CsA.

Authors:  Yun Hwa Jung; Sang Bong Han; Young Jae Park; In Sook Woo; Baik Kee Cho; Chi Wha Han
Journal:  Blood Res       Date:  2013-12-24

9.  Eosinophilia Associated With CD3-CD4+ T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients.

Authors:  Caroline Carpentier; Sylvain Verbanck; Liliane Schandené; Pierre Heimann; Anne-Laure Trépant; Elie Cogan; Florence Roufosse
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.